STOCK TITAN

[SCHEDULE 13G/A] TENAX THERAPEUTICS, INC. Amended Passive Investment Disclosure

(Neutral)
(Neutral)
Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

Tenax Therapeutics, Inc. reports that Logos Global Management and related reporting persons jointly disclose beneficial ownership of 800,000 shares of Common Stock, representing 3.0% of the class based on 26,525,159 shares outstanding as of May 8, 2026. The filing states shared voting and dispositive power for the 800,000 shares and is signed by William Arsani on behalf of the reporting persons on 05/15/2026.

Positive

  • None.

Negative

  • None.

Insights

Logos Global reports a 3.0% stake via shared control of 800,000 shares.

The filing lists 800,000 shares held with shared voting and dispositive power across Logos Global entities and William Arsani. The percentage is calculated using 26,525,159 shares outstanding as of May 8, 2026.

Filing language emphasizes advisory and partner relationships; cash‑flow treatment and plans for disposition are not stated. Subsequent filings would be needed to show any change in position.

Reported shares held 800,000 shares Amount beneficially owned by each reporting person
Percent of class 3.0% Percent of Common Stock based on outstanding shares
Shares outstanding (base) 26,525,159 shares Outstanding Common Stock used to calculate percentage as of <date>May 8, 2026</date>
Signature date 05/15/2026 Date filing was signed by William Arsani
Schedule 13G/A regulatory
"Amendment No. 1 and cover header referencing SCHEDULE 13G/A"
A Schedule 13G/A is an amended public filing with the U.S. securities regulator that updates a previous Schedule 13G, disclosing when an individual or group holds a substantial (typically over 5%) stake in a company and is claiming a passive, non‑controlling intent. Investors monitor these updates because rising or falling holdings can signal changing confidence, potential future moves, or shifts in voting power — like watching a public ledger where large shareholders quietly adjust their positions.
Beneficial ownership financial
"Amount beneficially owned: Logos Global: 800,000"
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.
Shared dispositive power financial
"Shared Dispositive Power 800,000.00 shown for reporting persons"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates

FAQ

What stake does Logos Global hold in Tenax Therapeutics (TENX)?

Logos Global and related persons report beneficial ownership of 800,000 shares, equal to 3.0% of the class. The percentage is based on 26,525,159 shares outstanding as of May 8, 2026, per the filing.

Who are the reporting persons on the Schedule 13G/A for TENX?

The filing is by Logos Global Management LP, Logos Global Management GP LLC, Logos Global Master Fund LP, Logos GP LLC, and William Arsani. William Arsani signed on behalf of the reporting persons on 05/15/2026.

What voting and dispositive powers are reported by Logos Global for TENX shares?

Each reporting person discloses 0 sole voting and 800,000 shared voting power; similarly 0 sole dispositive and 800,000 shared dispositive power for the Common Stock, as shown in the filing.

Does the Schedule 13G/A indicate Logos Global controls Tenax Therapeutics?

The filing includes a certification that the securities were not acquired to change or influence control. It states the holdings are not for control purposes and disclaims group membership; no controlling interest is claimed in the filing.





88032L605

(CUSIP Number)
03/31/2026

(Date of Event Which Requires Filing of this Statement)


Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)




schemaVersion:


SCHEDULE 13G




Comment for Type of Reporting Person: Percentage calculated based on 26,525,159 shares of Common Stock outstanding on May 8, 2026, as reported in the Form 10-Q filed by the Issuer for the quarter ended March 31, 2026.


SCHEDULE 13G




Comment for Type of Reporting Person: Percentage calculated based on 26,525,159 shares of Common Stock outstanding on May 8, 2026, as reported in the Form 10-Q filed by the Issuer for the quarter ended March 31, 2026.


SCHEDULE 13G




Comment for Type of Reporting Person: Percentage calculated based on 26,525,159 shares of Common Stock outstanding on May 8, 2026, as reported in the Form 10-Q filed by the Issuer for the quarter ended March 31, 2026.


SCHEDULE 13G




Comment for Type of Reporting Person: Percentage calculated based on 26,525,159 shares of Common Stock outstanding on May 8, 2026, as reported in the Form 10-Q filed by the Issuer for the quarter ended March 31, 2026.


SCHEDULE 13G




Comment for Type of Reporting Person: Percentage calculated based on 26,525,159 shares of Common Stock outstanding on May 8, 2026, as reported in the Form 10-Q filed by the Issuer for the quarter ended March 31, 2026.


SCHEDULE 13G



Logos Global Management LP
Signature:/s/ Arsani William
Name/Title:Managing Partner
Date:05/15/2026
Logos Global Management GP LLC
Signature:/s/ Arsani William
Name/Title:Managing Member
Date:05/15/2026
Logos Global Master Fund LP
Signature:/s/ Arsani William
Name/Title:Managing Member of Logos GP LLC, General Partner of Logos Global Master Fund LP
Date:05/15/2026
Logos GP LLC
Signature:/s/ Arsani William
Name/Title:Managing Member
Date:05/15/2026
Arsani William
Signature:/s/ Arsani William
Name/Title:Reporting person
Date:05/15/2026
Exhibit Information

EXHIBIT 99.1 - AGREEMENT REGARDING JOINT FILING OF STATEMENT ON SCHEDULE 13D OR 13G